{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-032071","form_type":"8-K","ticker":"OSTX","cik":"0001795091","company_name":"OS Therapies Inc","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.748049+00:00","generated_at":"2026-05-23T14:50:43.092729+00:00","sec_items":["2.01","3.02","1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"OS Therapies closes $8M asset acquisition from Ayala; eliminates $20M milestones, cuts royalty to 1.5%","bullets":["Total consideration $8M: $400k cash to Ayala, $100k to third party, $7.5M in stock (4,774,637 shares at VWAP).","Eliminated $3.5M Biologics License filing milestone and $16.5M in sales milestones for OST-HER2.","Royalty on OST-HER2, ADXS-503, ADXS-504 reduced from 10% to 1.5% of net sales (to Univ. of Pennsylvania).","Added three clinical-stage candidates (OST-AXAL for HPV, OST-503 for NSCLC, OST-PSA for prostate) and 8 preclinical constructs.","Issued 2,164,215 shares and a warrant for 2,166,381 shares (exercise $0.001, 3-yr term); additional 444,041 shares pending stockholder approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-032071","json":"https://secwatch.observer/filing/0001213900-25-032071.json","markdown":"https://secwatch.observer/filing/0001213900-25-032071.md","text":"https://secwatch.observer/filing/0001213900-25-032071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025032071/0001213900-25-032071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025032071/ea0238051-8k_ostherapies.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T14:50:43.092729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}